Description
Oxlumo (lumasiran) is a prescription medication used to treat primary hyperoxaluria type 1 (PH1), a rare genetic condition that causes the overproduction of oxalate, leading to kidney and liver damage. Oxlumo is an RNA interference (RNAi) drug that targets the liver to reduce the production of oxalate, which can slow the progression of kidney and liver disease.
Uses:
Oxlumo is used to treat primary hyperoxaluria type 1 (PH1), a rare genetic condition that causes the overproduction of oxalate, leading to kidney and liver damage.
Storage Conditions:
Oxlumo should be stored refrigerated at 36°F to 46°F (2°C to 8°C) in its carton until the expiration date. It should be protected from light and should not be frozen.
Mechanism of Action:
Oxlumo (lumasiran) is an RNA interference (RNAi) drug that targets the liver to reduce the production of oxalate. PH1 results from a genetic mutation that leads to the overproduction of oxalate, causing kidney and liver damage. Oxlumo targets the liver to reduce the production of glycolate oxidase, an enzyme involved in the production of oxalate. By reducing oxalate production, Oxlumo can slow the progression of kidney and liver disease.
HOW TO USE:
Oxlumo is administered as a subcutaneous injection by a healthcare provider. The recommended dosage is 3 mg/kg once monthly. The injection should be given in the stomach, thigh, or upper arm.
Precautions:
• Patients should inform their healthcare provider if they have liver or kidney problems, bleeding disorders, or are pregnant or planning to become pregnant.
• Patients taking Oxlumo may be at increased risk of infections, including upper respiratory infections. They should contact their healthcare provider if they develop symptoms of an infection, such as fever, cough, or sore throat.
Drug Interactions:
• There are no known drug interactions with Oxlumo.
Contraindications:
• Oxlumo should not be used in patients with a known hypersensitivity to the medication or its components.
Overdose:
There is limited information on the overdose of Oxlumo. However, patients who experience an overdose of Oxlumo should seek immediate medical attention.
Adverse Reactions:
The most common adverse reactions experienced by patients taking Oxlumo include injection site reactions, such as pain, redness, or swelling. Other potential side effects include nausea, abdominal pain, and liver enzyme abnormalities. Patients should contact their healthcare provider if they experience any unusual symptoms while taking Oxlumo.
In conclusion, Oxlumo (lumasiran) is an RNA interference (RNAi) drug that targets the liver to reduce the production of oxalate and treat primary hyperoxaluria type 1 (PH1). The recommended dosage is 3 mg/kg administered as a subcutaneous injection once monthly. Before taking Oxlumo, patients should inform their healthcare provider of any liver or kidney problems, bleeding disorders, or pregnancy. Adverse reactions may include injection site reactions, nausea, abdominal pain, and liver enzyme abnormalities. Oxlumo should not be used by those with hypersensitivity to the medication or its components. There are no known drug interactions with Oxlumo, but patients may be at increased risk of infections while taking it, and they should contact their healthcare provider if they develop symptoms of an infection.
Reviews
There are no reviews yet.